Johnson & Johnson boosted its research efforts in Alzheimer's on Monday by striking a deal potentially worth up to $509 million with unlisted Swiss biotech firm AC Immune to develop so-called anti-tau vaccines.
Tau is a protein known for forming tangles inside brain cells and is linked to cell death. It is one of two abnormal proteins tied to the memory-robbing disease. The other is beta amyloid.
Also read: Iran welcomes OPEC production cut decision